Table 2.
Osteoporosis therapies not currently approved in the US
| Drug | Effect | Mechanism of action | Dosing | Status |
|---|---|---|---|---|
| Strontium ranelate | Anabolic and antiresorptive | Calcium-like atom; stimulates osteoblasts and inhibits osteoclasts | Oral | Approved in Europe since 2004; Related compound, strontium malonate, in clinical trials in US |
| Odanacatib | Antiresorptive | Cathepsin K inhibitor | Oral | In Phase III trials in the US |
| Ostabolin-C | Anabolic | Parathyroid hormone analog; stimulates osteoblasts via PTH receptor-1 | Subcutaneous | In Phase III trials in the US |
| Lasofoxifene | Antiresorptive | SERM | Oral | Approved in Europe since 2009; in Phase III trials in the US |
| Bazedoxifene | Antiresorptive | SERM | Oral | Approved in Europe since 2009; US approval pending additional information as of April 2010 |
| Denosumab | Antiresorptive | Anti-RANKL monoclonal antibody | Subcutaneous | Approval in US and Europe expected in 2010 |